Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
PjSkSGPL1KNeXrFb
